{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:52:13Z","timestamp":1790779933871,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"am","delay-in-days":288,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.neuropharm.2022.109025","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T19:58:53Z","timestamp":1646769533000},"page":"109025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques"],"prefix":"10.1016","volume":"210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0970-420X","authenticated-orcid":false,"given":"R.","family":"Depoort\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Beardsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.I.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3203-1966","authenticated-orcid":false,"given":"C.A.","family":"Paronis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Walentiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7818-5266","authenticated-orcid":false,"given":"M.A.","family":"Varney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109025_bib1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00213-004-2031-3","article-title":"Differential effects of intra-midbrain raphe and systemic 8-OH-DPAT on VTA self-stimulation thresholds in rats","volume":"178","author":"Ahn","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109025_bib2","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1360-0443.1991.tb01747.x","article-title":"Drug abuse potential evaluation in animals","volume":"86","author":"Balster","year":"1991","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.neuropharm.2022.109025_bib3","series-title":"Nonclinical Drug Safety Assessment: Practical Considerations for Successful Registration FDAnews","first-page":"441","article-title":"Assessing dependency and abuse potential","author":"Beardsley","year":"2007"},{"key":"10.1016\/j.neuropharm.2022.109025_bib4","series-title":"Nonclinical Assessment of Abuse Potential for New Pharmaceuticals","first-page":"197","article-title":"Utility of intracranial self-stimulation in the assessment of the abuse liability of new pharmaceuticals","author":"Bespalov","year":"2015"},{"key":"10.1016\/j.neuropharm.2022.109025_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0028-3908(97)00010-5","article-title":"Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists","volume":"36","author":"Callahan","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109025_bib6","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1038\/nprot.2007.441","article-title":"Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation","volume":"2","author":"Carlezon","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2022.109025_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s002130050151","article-title":"Microinjections of phencyclidine (PCP) and related drugs into nucleus accumbens shell potentiate medial forebrain bundle brain stimulation reward","volume":"128","author":"Carlezon","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109025_bib8","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/jpet.105.095109","article-title":"High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperallodynia and affective conditioning","volume":"316","author":"Colpaert","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109025_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130050586","article-title":"The discriminative stimulus properties of cocaine: effects of microinfusion of cocaine, a 5-HT1A agonist or antagonist, into the ventral tegmental area","volume":"137","author":"De La Garza","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109025_bib10","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/mds.27101","article-title":"Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease","volume":"32","author":"Delpont","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2022.109025_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.parkreldis.2020.08.009","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques","volume":"78","author":"Depoortere","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2022.109025_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00414409","article-title":"Effects of d-amphetamine, scopolamine, chlordiazepoxide and diphenylhydantoin on self-stimulation behavior and brain acetylcholine","volume":"23","author":"Domino","year":"1972","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109025_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/neurolint12030014","article-title":"Chronic pain treatment strategies in Parkinson's disease","volume":"12","author":"Edinoff","year":"2020","journal-title":"Neurol. Int."},{"key":"10.1016\/j.neuropharm.2022.109025_bib14","doi-asserted-by":"crossref","first-page":"107997","DOI":"10.1016\/j.neuropharm.2020.107997","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets","volume":"167","author":"Fisher","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109025_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109025_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-3565(24)29542-2","article-title":"Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors","volume":"297","author":"Harrison","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109025_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.expneurol.2015.05.021","article-title":"NLX-112, a novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: behavioral and neurochemical profile in rat","volume":"271","author":"Iderberg","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109025_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.expneurol.2015.05.021","article-title":"NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: behavioral and neurochemical profile in rat","volume":"271","author":"Iderberg","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109025_bib19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pbb.2004.07.015","article-title":"Effect of 5-HT1B\/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets","volume":"79","author":"Jackson","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109025_bib20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00702-011-0703-9","article-title":"Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression","volume":"118","author":"Jenner","year":"2011","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2022.109025_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)39359-6","article-title":"The discriminative stimulus effects of cocaine in pigeons","volume":"267","author":"Johanson","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109025_bib22","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0022-3565(24)37310-0","article-title":"Discriminative stimulus properties of cocaine: enhancement by monoamine reuptake blockers","volume":"284","author":"Kleven","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109025_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00421261","article-title":"Effects of heroin on lever pressing for intracranial self-stimulation, food and water in the rat","volume":"42","author":"Koob","year":"1975","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109025_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF01244460","article-title":"5-HT1A agonists and dopamine: the effects of 8-OH-DPAT and buspirone on brain-stimulation reward","volume":"83","author":"Montgomery","year":"1991","journal-title":"J. Neural Transm. Gen. Sect."},{"key":"10.1016\/j.neuropharm.2022.109025_bib25","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00008877-199410000-00004","article-title":"Blockade of the discriminative stimulus effects of d-amphetamine in rhesus monkeys with serotonin 5-HT(1A) agonists","volume":"5","author":"Nader","year":"1994","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109025_bib26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/pr.112.007419","article-title":"Intracranial self-stimulation to evaluate abuse potential of drugs","volume":"66","author":"Negus","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109025_bib27","first-page":"107937","article-title":"Translating biased agonists from molecules to medications: serotonin 5-HT1A receptor functional selectivity for CNS disorders","author":"Newman-Tancredi","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109025_bib28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0022-3565(25)25771-8","article-title":"Effects of chlorpromazine, meprobamate, pentobarbital and morphine on self-stimulation","volume":"128","author":"Olds","year":"1960","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109025_bib29","series-title":"WO2016\/005527A1","article-title":"A method for treating movement disorders with befiradol","author":"Paillard","year":"2016"},{"key":"10.1016\/j.neuropharm.2022.109025_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00008877-199712000-00004","article-title":"Stimulation of serotonin (5-HT)1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats","volume":"8","author":"Przegalinski","year":"1997","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109025_bib31","first-page":"2174","article-title":"Illicit fentanyl driving opioid overdose deaths","volume":"318","author":"Rubin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2022.109025_bib32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1874473710902030273","article-title":"Substance abuse and movement disorders","volume":"2","author":"San Luciano","year":"2009","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.neuropharm.2022.109025_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-018-0653-7","article-title":"Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia","volume":"7","author":"Sellnow","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuropharm.2022.109025_bib34","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/j.1875-9114.1997.tb03794.x","article-title":"Levodopa dependence and abuse in Parkinson's disease","volume":"17","author":"Spigset","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2022.109025_bib35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.vascn.2016.05.011","article-title":"Drug discrimination: a versatile tool for characterization of CNS safety pharmacology and potential for drug abuse","volume":"81","author":"Swedberg","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.neuropharm.2022.109025_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1300\/J251v09n01_03","article-title":"The opioids: abuse liability and treatments for dependence","volume":"9","author":"Ternes","year":"1990","journal-title":"Adv. Alcohol Subst. Abuse"},{"key":"10.1016\/j.neuropharm.2022.109025_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF00421372","article-title":"Intracranial self-stimulation in rats as a function of various stimulus parameters. V. Influence of cocaine on medial forebrain bundle stimulation with monopolar electrodes","volume":"38","author":"Wauquier","year":"1974","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109025_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.ne.19.030196.001535","article-title":"Addictive drugs and brain stimulation reward","volume":"19","author":"Wise","year":"1996","journal-title":"Annu. Rev. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:16:50Z","timestamp":1758439010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"alternative-id":["S0028390822000843"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109025","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109025"}}